This week, Christopher Hourigan, director of the Fralin Institute for Biomedical Research Cancer Research Center in Washington, DC, will be inducted into the American Society for Clinical Investigation (ASCI), a historic membership for a Virginia Tech faculty member.
Mr. Hourigan, previously a tenured senior scientist and director of the Myeloid Malignancies Laboratory at the National Institutes of Health, announced on Monday, April 1, that he will become a professor at VTC's Fralin Institute for Biomedical Research and the institute's Cancer Research Center. He joined Virginia Tech as director.in washington d.c.
“Mr. Hourigan's induction into the prestigious Medical Honor Society, which has a tradition spanning more than 100 years, marks an important milestone for Virginia Tech,” said Dr. said Michael Friedlander, vice president of technology. “This distinguished membership includes many men and women who represent the pinnacle of achievement, including Nobel Prize and Lasker Prize winners. Dr. Hourigan's participation honors Virginia Tech and honors the University's We will enhance our global standing.”
Friedlander said Virginia Tech has reached an important milestone on its path to becoming a comprehensive academic medical enterprise that includes excellence in basic, translational, and clinical research.
“Dr. Hourigan’s innovative and tenacious efforts to better understand patients with relapsed myeloid leukemia so that we can provide the best, most individualized treatment are key to this important milestone in cancer research.” It's at the forefront of the field,” Friedlander said. “His research provides evidence-based hope in a very individualized way for individuals facing the fear of a recurring disease.”
Members of the American Society for Clinical Investigation must be physicians who have “made a mark on original, creative, and independent research in clinical medicine” and who enjoy “impeccable moral standing in the medical profession.” It won't.
“ASCI is one of the nation's oldest medical honor societies and one of the few that focuses on the special role of physician-scientists,” said Lee Lierman, dean of the Virginia Tech Carilion School of Medicine. said. “Dr. Horrigan is a perfect example. His extensive career as a distinguished scientist and precision oncologist has enabled him to take discoveries from the bench to the bedside and back again, leading to new treatments. We are excited that he has joined the Virginia Tech Carilion School of Medicine as a tenured faculty member in conjunction with his appointment as lead faculty member in VTC's Fralin Biomedical Research Institute. By connecting with collaborators at Virginia Tech, across the nation, and around the world, we look forward to Dr. Hourigan leading innovations that will revolutionize our approach to cancer treatment.”
Professor Hourigan joined the National Heart, Lung, and Blood Institute's Intramural Research Program at the National Institutes of Health in 2012 to bring scientific, clinical, and technical expertise to address the difficult problem of measurable residual disease. We have started a malignant tumor laboratory. Patients with acute myeloid leukemia (AML).
“My membership in this medical honor society is based on my team's efforts over the past 12 years to use the best scientific tools to understand and improve the practice of medicine,” Hourigan said. Stated. “As oncologists, we ask our patients to make life-changing decisions, often based on limited information. We focused on specific examples of patients who were said to be in remission and showed that it is possible to identify high-risk patients who may benefit from personalized treatment. .”
Hourigan and Benjamin Ebert, chief of medical oncology at Dana-Farber Cancer Institute, and leukemia specialist and physician-scientist at Memorial Sloan Kettering Cancer Center, and senior director of translational research at Memorial University. Recommended to membership by Vice President Ross Levine. hospital.
“Dr. Hourigan is a highly disciplined physician-scientist who brings outstanding scientific, clinical, and technical expertise to address the difficult problem of measurable residual disease in patients with acute myeloid leukemia.” ,” George P. Kanelos, M.D., said Evert. , M.D., and Gene S. Kanelos Professor of Medicine at Harvard Medical School and Howard Hughes Medical Institute Investigator. “Dr. Hourigan is definitely one of the few researchers at the forefront of this field.”
Similarly, Levine said Hourigan is a remarkable example of a physician-scientist whose groundbreaking work on minimal residual disease in acute myeloid leukemia has transformed patient care and research. He emphasized that he had an impact.
“Chris is the quintessential physician-scientist who uses his clinical medicine as a foundation to ask and investigate important scientific questions in the laboratory and then brings those insights back to the clinic,” said the statement, which focuses on blood and bone marrow research and treatment. said Levine, who is guessing. cancer. “He is an exemplary scientist and clinician, and his use of genomics to answer important questions related to the scientific and clinical fields is world class. His research is leading the field. and is changing the way AML patients are monitored and treated.”
Mr. Hourigan was inducted into the Hall of Fame on Friday, April 5, in Chicago.
Disclaimer: AAAS and EurekAlert! We are not responsible for the accuracy of news releases posted on EurekAlert! Use of Information by Contributing Institutions or via the EurekAlert System.
